Pacgen Life Science Corporation acquired by Taiwan-based pharma company

Date Closed

September 30, 2020

Lead Office



1.78 Million CAD

On September 30, 2020, Pacgen Life Science Corporation (Pacgen) was acquired by General Biologicals Corporation (GBC), a Taiwan-based diagnostic and pharmaceutical company. The transaction took place by way of a court-approved plan of arrangement, through which GBC acquired all outstanding shares of Pacgen in an all cash transaction.

The implied equity value of the plan of arrangement is C$1.782 million.

Pacgen is a life sciences company that sells and markets over sixty different products in oral care, skin care and health supplement segments.

McCarthy Tétrault advised Pacgen with a team led by Robin Mahood that included Miranda Lam, Xinya Wang, Alyssa Leung and Firuz Rahimi (M&A), Vincent Yip (Intellectual Property), and Jeremy Ho (Tax).